QuantumPharm Inc. (HKG: 2228)
Hong Kong
· Delayed Price · Currency is HKD
3.950
-0.090 (-2.23%)
Nov 22, 2024, 10:21 AM HKT
QuantumPharm Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 |
Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue | 197.08 | 174.42 | 133.35 | 62.8 |
Revenue Growth (YoY) | 213.83% | 30.80% | 112.35% | - |
Cost of Revenue | 104.8 | 107.57 | 60.1 | 27.42 |
Gross Profit | 92.29 | 66.85 | 73.25 | 35.38 |
Selling, General & Admin | 541.67 | 414.93 | 295.59 | 177.88 |
Research & Development | 430.18 | 442.8 | 315.36 | 201.76 |
Other Operating Expenses | -79.94 | -72.12 | 5.28 | -16.42 |
Operating Expenses | 891.92 | 785.61 | 616.22 | 363.22 |
Operating Income | -799.63 | -718.77 | -542.97 | -327.84 |
Interest Expense | -9.46 | -9.58 | -5.75 | -3.58 |
Interest & Investment Income | 88.39 | 102.69 | 50.48 | 14.06 |
Earnings From Equity Investments | -2.97 | -1.96 | -0.24 | -4.5 |
Currency Exchange Gain (Loss) | 5.47 | -40.37 | 5.91 | 9.43 |
EBT Excluding Unusual Items | -718.2 | -667.98 | -492.56 | -312.43 |
Gain (Loss) on Sale of Investments | 38.16 | -4.38 | -9.62 | 10.36 |
Other Unusual Items | -1,844 | -1,234 | -936.43 | -1,835 |
Pretax Income | -2,524 | -1,906 | -1,439 | -2,137 |
Earnings From Continuing Operations | -2,524 | -1,906 | -1,439 | -2,137 |
Minority Interest in Earnings | -14.82 | -8.06 | 0.11 | 0.04 |
Net Income | -2,538 | -1,914 | -1,439 | -2,137 |
Net Income to Common | -2,538 | -1,914 | -1,439 | -2,137 |
Shares Outstanding (Basic) | 607 | 484 | 484 | 482 |
Shares Outstanding (Diluted) | 607 | 484 | 484 | 482 |
Shares Change (YoY) | 25.77% | - | 0.35% | - |
EPS (Basic) | -4.18 | -3.96 | -2.97 | -4.43 |
EPS (Diluted) | -4.19 | -3.96 | -2.97 | -4.43 |
Free Cash Flow | -681 | -691.36 | -622.52 | -414.32 |
Free Cash Flow Per Share | -1.12 | -1.43 | -1.29 | -0.86 |
Gross Margin | 46.83% | 38.32% | 54.93% | 56.34% |
Operating Margin | -405.73% | -412.09% | -407.17% | -522.05% |
Profit Margin | -1287.98% | -1097.57% | -1078.72% | -3403.38% |
Free Cash Flow Margin | -345.54% | -396.37% | -466.82% | -659.76% |
EBITDA | -717.4 | -647.96 | -495 | -315.45 |
D&A For EBITDA | 82.23 | 70.81 | 47.97 | 12.4 |
EBIT | -799.63 | -718.77 | -542.97 | -327.84 |
Source: S&P Capital IQ. Standard template.
Financial Sources.